117 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Hemophilia A"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Socialization of Adult Men With Congenital Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention:
2 Recruiting A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: MOD-5014
3 Recruiting An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: ALN-AT3SC
4 Recruiting An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Conditions: Hemophilia A;   Severe Hemophilia A
Intervention: Biological: rVIII‑SingleChain
5 Recruiting Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
Conditions: Hemophilia A;   Hemophilia B;   Von Willebrand's Disease
Intervention:
6 Not yet recruiting Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A
Condition: Hemophilia A
Intervention: Drug: ADVATE
7 Not yet recruiting Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Recombinant Human Coagulation Factor VIII for injection
8 Recruiting PK Driven Prophylaxis for Hemophilia A
Condition: Hemophilia A
Intervention: Device: MyPKFiT
9 Recruiting Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
Condition: Hemophilia A
Intervention: Drug: Plasma-derived FVIII/VWF concentrate
10 Recruiting Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A
Condition: Hemophilia A
Intervention: Biological: BAY94-9027
11 Not yet recruiting Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients
Conditions: Hemophilia A;   Factor VIII
Intervention: Drug: Recombinant VIII factor
12 Recruiting Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
Condition: Hemophilia A
Intervention:
13 Recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: rFVIIIFc
14 Recruiting Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: Alphanate SD/HT
15 Not yet recruiting Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors
Condition: Hemophilia A With Inhibitor
Intervention:
16 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
17 Recruiting Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Condition: Haemophilia A
Intervention: Biological: Optivate 500IU
18 Not yet recruiting Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."
Condition: Hemophilia A
Intervention: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
19 Recruiting Gene Therapy Study in Severe Haemophilia A Patients
Condition: Severe Haemophilia A
Intervention: Genetic: BMN 270
20 Recruiting A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients From ≥6 Months Old to <12 Years Old With Inhibitors to Factor VIII or IX
Conditions: Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
Intervention: Biological: Coagulation FVIIa (Recombinant)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years